Total Payments
$1,083
2024 Payments
$115.57
Companies
17
Transactions
30
Medicare Patients
1,664
Medicare Billing
$328,218
Payment Breakdown by Category
Food & Beverage$756.74 (69.9%)
Education$326.08 (30.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $756.74 | 13 | 69.9% |
| Education | $326.08 | 17 | 30.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Inari Medical, Inc. | $181.24 | 1 | $0 (2021) |
| PFIZER INC. | $172.47 | 9 | $0 (2024) |
| Covidien LP | $128.17 | 1 | $0 (2019) |
| Myovant Sciences Inc. | $112.01 | 2 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $106.84 | 1 | $0 (2019) |
| Focal Therapeutics, Inc. | $79.53 | 1 | $0 (2017) |
| Sumitomo Pharma America, Inc. | $71.79 | 3 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $32.46 | 2 | $0 (2024) |
| ERBE USA Inc | $31.43 | 1 | $0 (2023) |
| Amgen Inc. | $28.96 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $115.57 | 6 | Ipsen Biopharmaceuticals, Inc ($32.46) |
| 2023 | $182.78 | 8 | PFIZER INC. ($69.60) |
| 2022 | $186.43 | 7 | Myovant Sciences Inc. ($88.08) |
| 2021 | $205.17 | 2 | Inari Medical, Inc. ($181.24) |
| 2019 | $298.45 | 5 | Covidien LP ($128.17) |
| 2017 | $94.42 | 2 | Focal Therapeutics, Inc. ($79.53) |
All Payment Transactions
30 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $18.56 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 08/20/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Education | In-kind items and services | $16.23 | General |
| Category: Oncology | ||||||
| 04/16/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Tazverik | Education | In-kind items and services | $16.23 | General |
| Category: Oncology | ||||||
| 02/28/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $22.53 | General |
| 01/23/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Education | In-kind items and services | $23.93 | General |
| Category: HORMONE THERAPY | ||||||
| 11/08/2023 | Penumbra, Inc. | Indigo System (Device) | Food and Beverage | Cash or cash equivalent | $15.15 | General |
| Category: Peripheral Intervention | ||||||
| 10/26/2023 | ERBE USA Inc | Erbe CRYO2 (Device) | Food and Beverage | Cash or cash equivalent | $31.43 | General |
| Category: Oncology | ||||||
| 10/11/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $31.80 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $18.74 | General |
| Category: Oncology | ||||||
| 08/18/2023 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Education | In-kind items and services | $23.93 | General |
| Category: HORMONE THERAPY | ||||||
| 03/10/2023 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Education | In-kind items and services | $23.93 | General |
| Category: HORMONE THERAPY | ||||||
| 12/05/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $31.20 | General |
| Category: ONCOLOGY | ||||||
| 10/14/2022 | GlaxoSmithKline, LLC. | BLENREP (Biological) | Food and Beverage | In-kind items and services | $14.53 | General |
| Category: ONCOLOGY | ||||||
| 07/20/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $13.92 | General |
| Category: ONCOLOGY | ||||||
| 07/20/2022 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.80 | General |
| Category: ONCOLOGY | ||||||
| 03/15/2022 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $13.93 | General |
| Category: ONCOLOGY | ||||||
| 02/22/2022 | Myovant Sciences Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $88.08 | General |
| Category: HORMONE THERAPY | ||||||
| 01/27/2022 | Acrotech Biopharma LLC | BELEODAQ (Drug) | Education | In-kind items and services | $11.97 | General |
| Category: ONCOLOGY | ||||||
| 10/08/2021 | Myovant Sciences Inc. | ORGOVYX (Drug) | Education | In-kind items and services | $23.93 | General |
| Category: HORMONE THERAPY | ||||||
| 04/27/2021 | Inari Medical, Inc. | FLOWTRIEVER CATHETER, S (Device), FLOWTRIEVER CATHETER, S | Food and Beverage | In-kind items and services | $181.24 | General |
| Category: VTE | ||||||
| 10/23/2019 | Covidien LP | Beacon (Device) | Food and Beverage | In-kind items and services | $128.17 | General |
| Category: Ablation | ||||||
| 10/22/2019 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $106.84 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 324 | 763 | $176,890 | $67,953 |
| 2022 | 8 | 388 | 862 | $198,985 | $76,250 |
| 2021 | 10 | 427 | 860 | $190,232 | $75,731 |
| 2020 | 11 | 525 | 2,555 | $312,659 | $108,285 |
Total Patients
1,664
Total Services
5,040
Medicare Billing
$328,218
Procedure Codes
34
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 172 | 601 | $134,624 | $52,253 | 38.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 28 | 28 | $12,124 | $4,401 | 36.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 29 | 33 | $9,999 | $4,355 | 43.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 64 | 70 | $11,060 | $3,951 | 35.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 31 | 31 | $9,083 | $2,993 | 33.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 179 | 628 | $140,672 | $54,931 | 39.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 36 | 36 | $15,588 | $5,818 | 37.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 70 | 77 | $12,166 | $4,470 | 36.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 24 | 33 | $9,999 | $4,469 | 44.7% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 25 | 25 | $5,425 | $1,821 | 33.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 17 | 17 | $4,981 | $1,666 | 33.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 16 | 16 | $5,504 | $1,655 | 30.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 21 | 30 | $4,650 | $1,419 | 30.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 187 | 574 | $128,576 | $52,650 | 40.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 48 | 48 | $20,784 | $7,752 | 37.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 40 | 75 | $11,625 | $4,019 | 34.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 53 | 54 | $8,532 | $3,263 | 38.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 19 | 24 | $7,272 | $3,205 | 44.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 15 | 19 | $4,237 | $1,359 | 32.1% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 16 | 17 | $3,689 | $1,326 | 35.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 11 | 11 | $3,223 | $1,157 | 35.9% |
| 0012A | Adm sarscov2 100mcg/0.5ml2nd | Office | 2021 | 17 | 17 | $1,496 | $627.98 | 42.0% |
| 0011A | Adm sarscov2 100mcg/0.5ml1st | Office | 2021 | 21 | 21 | $798.00 | $372.75 | 46.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 216 | 712 | $159,488 | $53,875 | 33.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2020 | 11 | 1,380 | $59,340 | $20,867 | 35.2% |
About Dr. Leslie Walker, MD
Dr. Leslie Walker, MD is a Hematology & Oncology healthcare provider based in Tulsa, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1275576118.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Leslie Walker, MD has received a total of $1,083 in payments from pharmaceutical and medical device companies, with $115.57 received in 2024. These payments were reported across 30 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($756.74).
As a Medicare-enrolled provider, Walker has provided services to 1,664 Medicare beneficiaries, totaling 5,040 services with total Medicare billing of $328,218. Data is available for 4 years (2020–2023), covering 34 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Tulsa, OK
- Active Since 06/14/2006
- Last Updated 01/12/2016
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1275576118
Products in Payments
- ORGOVYX (Drug) $183.80
- FLOWTRIEVER CATHETER, S (Device) $181.24
- IBRANCE (Drug) $142.41
- Beacon (Device) $128.17
- LYNPARZA (Drug) $106.84
- BioZorb (Device) $79.53
- Onivyde (Drug) $32.46
- Erbe CRYO2 (Device) $31.43
- Nplate (Biological) $28.96
- BELEODAQ (Drug) $25.90
- MEKINIST (Drug) $22.98
- ERLEADA (Drug) $18.74
- ELIQUIS (Drug) $18.56
- WELIREG (Drug) $18.09
- Indigo System (Device) $15.15
- BLENREP (Biological) $14.53
- XTANDI (Drug) $11.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Tulsa
Dr. Edwin Mccreary, M.d, M.D
Hematology & Oncology — Payments: $477,532
Hematology & Oncology $477,532
Dr. Ali Moussa, M.d, M.D
Hematology & Oncology — Payments: $11,003
Hematology & Oncology $11,003
Supriya Koya, Md, MD
Hematology & Oncology — Payments: $6,558
Hematology & Oncology $6,558
Dr. Vicki Baker, M.d, M.D
Hematology & Oncology — Payments: $5,946
Hematology & Oncology $5,946
Dr. Mark Olsen, M.d, M.D
Hematology & Oncology — Payments: $4,652
Hematology & Oncology $4,652
Dr. Jennifer Trottman, Md, MD
Hematology & Oncology — Payments: $4,488
Hematology & Oncology $4,488